Business
Grant of Share Options
Grant of Share Options.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n \n \n 22 February 2023\n \n \n \n ONDINE BIOMEDICAL INC.\n \n \n \n (\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n \n \n \n Grant of Share Options\n \n \n \n Ondine Biomedical Inc. (AIM: OBI)\n announces that on 21 February 2023 it granted a total of 300,000 options to subscribe for new common shares in the Company (\"Options\") to its Non-executive Directors as follows:\n \n \n \n \n \n \n \n Director\n \n \n \n \n \n \n Position\n \n \n \n \n \n \n Options granted\n \n \n \n \n \n \n Exercise price\n \n \n \n \n \n \n Total options now held\n \n \n \n \n \n \n \n Jean Charest\n \n \n \n \n Non-executive Chair\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 100,000\n \n \n \n \n \n \n Craig Tooman\n \n \n \n \n Non-executive Director\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 150,000\n \n \n \n \n \n \n Jean Duvall\n \n \n \n \n Non-executive Director\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 150,000\n \n \n \n \n \n \n Mike Farrar\n \n \n \n \n Non-executive Director\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 50,000\n \n \n \n \n \n \n Junaid Bajwa\n \n \n \n \n Non-executive Director\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 50,000\n \n \n \n \n \n \n Simon Sinclair\n \n \n \n \n Non-executive Director\n \n \n \n \n 50,000\n \n \n \n \n 21.5p\n \n \n \n \n 50,000\n \n \n \n \n \n \n \n \n \n The Options all have an exercise price of 21.5p, being the closing share price on 8 December 2022 (the \"Approval Date\"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of 4 years, with a quarter vesting on each of the four successive anniversaries of the Approval Date, and can be exercised for a period of five years from the Approval Date.\n \n \n Following the grant of the Options, the Company has 7,870,000 options to subscribe for new common shares outstanding, which represents 4.04 per cent of the Company's current issued share capital.\n \n \n The FCA notifications in respect of the above Option grants, made in accordance with the requirements of the UK Market Abuse Regulation, are appended below.\n \n \n \n \n \n \n \n Ondine Biomedical Inc. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Angelika Vance, Corporate Communications\n \n \n \n \n +001 (1) 604 838 2702\n \n \n \n \n \n \n \n \...